Rehena Z, Ghosh C K, Afroz F, Alam M B, Ferdousi S, Mahmuduzzaman M, Sultana T, Ahmed A N
Dr Zinat Rehena, Clinical Pathologist, Department of Clinical Pathology, Sir Salimullah Medial College and Mitford Hospital, Dhaka, Bangladesh; E-mail:
Mymensingh Med J. 2015 Jul;24(3):542-9.
Several serum tumour markers have been described for gastric cancer. Preoperative level of tumor marker helps to predict the diagnosis of gastric carcinoma. CA72-4 as a serum tumour marker for gastric cancer is evaluated, and compared its utility in this regard with that of carcinoembryonic antigen (CEA). Analysis of gastric carcinoma by serum levels of CEA and CA72-4 and their correlation with histopathology help the clinician to develop his management strategies for gastric carcinoma. A prospective observational study was carried out in the Department of Clinical Pathology, Bangabandhu Sheikh Mujib Medical University (BSMMU) in collaboration with Department of Surgery BSMMU, DMCH, Delta Hospital Limited, Dhaka, during the period of October 2010 to September 2011. Serum CA72-4 and CEA were analyzed in 71 endoscopically suspected patients for gastric carcinoma. Among them 58 cases were diagnosed as malignant gastric disease and 13 cases were nonmalignant gastric disease. Sensitivity of CA 72-4 and CEA were 48.3% and 31% respectively and specificity were 92.3% and 76.9% respectively. In poorly differentiated carcinoma, positivity for CA72-4 and CEA were 55.6% and 36.1% respectively. Because of the high positivity of CA72-4 in poorly differentiated carcinoma, CA72-4 is reliable tumour marker in advanced cases. As the sensitivity of CA72-4 was more than that of CEA in diagnosis of gastric cancer, CA72-4 can be used in conjunction with other diagnostic tests like endoscopy that would be more helpful for the patients.
已经描述了几种用于胃癌的血清肿瘤标志物。术前肿瘤标志物水平有助于预测胃癌的诊断。对作为胃癌血清肿瘤标志物的CA72 - 4进行评估，并将其在这方面的效用与癌胚抗原（CEA）的效用进行比较。通过CEA和CA72 - 4的血清水平分析胃癌及其与组织病理学的相关性，有助于临床医生制定胃癌的治疗策略。2010年10月至2011年9月期间，在班加班杜·谢赫·穆吉布医科大学（BSMMU）临床病理科与BSMMU外科、达卡医学学院医院（DMCH）、达卡三角洲医院有限公司合作开展了一项前瞻性观察研究。对71例经内镜怀疑为胃癌的患者进行了血清CA72 - 4和CEA分析。其中58例被诊断为恶性胃部疾病，13例为非恶性胃部疾病。CA72 - 4和CEA的敏感性分别为48.3%和31%，特异性分别为92.3%和76.9%。在低分化癌中，CA72 - 4和CEA的阳性率分别为55.6%和36.1%。由于CA72 - 4在低分化癌中的高阳性率，CA72 - 4在晚期病例中是可靠的肿瘤标志物。由于CA72 - 4在胃癌诊断中的敏感性高于CEA，CA72 - 4可与其他诊断测试如内镜检查联合使用，这对患者更有帮助。
